Is Biodexa Pharmaceticals Stock a Good Investment?
Biodexa Pharmaceticals Investment Advice | BDRX |
- Examine Biodexa Pharmaceticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Biodexa Pharmaceticals' leadership team and their track record. Good management can help Biodexa Pharmaceticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Biodexa Pharmaceticals' business and its evolving consumer preferences.
- Compare Biodexa Pharmaceticals' performance and market position to its competitors. Analyze how Biodexa Pharmaceticals is positioned in terms of product offerings, innovation, and market share.
- Check if Biodexa Pharmaceticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Biodexa Pharmaceticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Biodexa Pharmaceticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Biodexa Pharmaceticals is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Biodexa Pharmaceticals Stock
Researching Biodexa Pharmaceticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 38.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.26. Some equities with similar Price to Book (P/B) outperform the market in the long run. Biodexa Pharmaceticals recorded a loss per share of 75.55. The entity last dividend was issued on the 3rd of March 2020. The firm had 1:25 split on the 4th of October 2024.
To determine if Biodexa Pharmaceticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Biodexa Pharmaceticals' research are outlined below:
| Biodexa Pharmaceticals generated a negative expected return over the last 90 days | |
| Biodexa Pharmaceticals has high historical volatility and very poor performance | |
| Biodexa Pharmaceticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 381 K. Net Loss for the year was (7.08 M) with loss before overhead, payroll, taxes, and interest of (4.41 M). | |
| Biodexa Pharmaceticals generates negative cash flow from operations | |
| Biodexa Pharmaceticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Result of General Meeting |
Biodexa Pharmaceticals Quarterly Cash And Short Term Investments |
|
Biodexa Pharmaceticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Biodexa Pharmaceticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Biodexa Pharmaceticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Biodexa Pharmaceticals' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.89 M.Market Cap |
|
Biodexa Pharmaceticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.93) | (0.98) | |
| Return On Capital Employed | (1.61) | (1.53) | |
| Return On Assets | (0.67) | (0.71) | |
| Return On Equity | (1.51) | (1.59) |
Determining Biodexa Pharmaceticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Biodexa Pharmaceticals is a good buy. For example, gross profit margin measures Biodexa Pharmaceticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Biodexa Pharmaceticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Biodexa Pharmaceticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Biodexa Pharmaceticals. Check Biodexa Pharmaceticals' Beneish M Score to see the likelihood of Biodexa Pharmaceticals' management manipulating its earnings.
Evaluate Biodexa Pharmaceticals' management efficiency
Biodexa Pharmaceticals has return on total asset (ROA) of (0.3752) % which means that it has lost $0.3752 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9723) %, meaning that it created substantial loss on money invested by shareholders. Biodexa Pharmaceticals' management efficiency ratios could be used to measure how well Biodexa Pharmaceticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.98 in 2024. Return On Capital Employed is likely to rise to -1.53 in 2024. At this time, Biodexa Pharmaceticals' Total Assets are fairly stable compared to the past year. Other Assets is likely to rise to about 3.2 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 3.3 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 148.11 | 140.70 | |
| Tangible Book Value Per Share | 54.99 | 52.24 | |
| Enterprise Value Over EBITDA | 0.54 | 0.56 | |
| Price Book Value Ratio | 0.36 | 0.34 | |
| Enterprise Value Multiple | 0.54 | 0.56 | |
| Price Fair Value | 0.36 | 0.34 | |
| Enterprise Value | -3.8 M | -3.7 M |
The strategic initiatives led by Biodexa Pharmaceticals' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 1.438 |
Basic technical analysis of Biodexa Stock
As of the 27th of November, Biodexa Pharmaceticals shows the Standard Deviation of 11.76, mean deviation of 6.68, and Risk Adjusted Performance of (0.06). Biodexa Pharmaceticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Understand Biodexa Pharmaceticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Biodexa Pharmaceticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (0.34) | |||
| Mean Deviation | 6.68 | |||
| Coefficient Of Variation | (1,057) | |||
| Standard Deviation | 11.76 | |||
| Variance | 138.36 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (1.51) | |||
| Total Risk Alpha | (2.95) | |||
| Treynor Ratio | (0.35) | |||
| Maximum Drawdown | 97.78 | |||
| Value At Risk | (17.24) | |||
| Potential Upside | 11.91 | |||
| Skewness | 2.75 | |||
| Kurtosis | 17.91 |
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (0.34) | |||
| Mean Deviation | 6.68 | |||
| Coefficient Of Variation | (1,057) | |||
| Standard Deviation | 11.76 | |||
| Variance | 138.36 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (1.51) | |||
| Total Risk Alpha | (2.95) | |||
| Treynor Ratio | (0.35) | |||
| Maximum Drawdown | 97.78 | |||
| Value At Risk | (17.24) | |||
| Potential Upside | 11.91 | |||
| Skewness | 2.75 | |||
| Kurtosis | 17.91 |
Consider Biodexa Pharmaceticals' intraday indicators
Biodexa Pharmaceticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Biodexa Pharmaceticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 1456.65 | |||
| Daily Balance Of Power | (0.49) | |||
| Rate Of Daily Change | 0.96 | |||
| Day Median Price | 4.78 | |||
| Day Typical Price | 4.78 | |||
| Price Action Indicator | (0.07) | |||
| Period Momentum Indicator | (0.18) |
Biodexa Pharmaceticals Corporate Filings
13A | 20th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
6K | 12th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 5th of November 2024 Other Reports | ViewVerify | |
| 12th of August 2024 Other Reports | ViewVerify |
Biodexa Stock media impact
Far too much social signal, news, headlines, and media speculation about Biodexa Pharmaceticals that are available to investors today. That information is available publicly through Biodexa media outlets and privately through word of mouth or via Biodexa internal channels. However, regardless of the origin, that massive amount of Biodexa data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Biodexa Pharmaceticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Biodexa Pharmaceticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Biodexa Pharmaceticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Biodexa Pharmaceticals alpha.
Biodexa Pharmaceticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Biodexa Pharmaceticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Biodexa Pharmaceticals Corporate Management
| Nicola Tuckwell | VP Operations | Profile | |
| Dmitry MD | Chief Officer | Profile | |
| Daniel MBA | Vice Technology | Profile | |
| Fiona Sharp | Group Controller | Profile | |
| Steve Ellul | Chief Officer | Profile |
Additional Tools for Biodexa Stock Analysis
When running Biodexa Pharmaceticals' price analysis, check to measure Biodexa Pharmaceticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodexa Pharmaceticals is operating at the current time. Most of Biodexa Pharmaceticals' value examination focuses on studying past and present price action to predict the probability of Biodexa Pharmaceticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodexa Pharmaceticals' price. Additionally, you may evaluate how the addition of Biodexa Pharmaceticals to your portfolios can decrease your overall portfolio volatility.